Kazia Therapeutics Limited (NASDAQ:KZIA) Short Interest Update

Kazia Therapeutics Limited (NASDAQ:KZIA) saw a large decline in short interest in November. As of November 30th, there was short interest totalling 22,300 shares, a decline of 36.3% from the November 15th total of 35,000 shares. Based on an average trading volume of 146,500 shares, the days-to-cover ratio is presently 0.2 days.

Kazia Therapeutics Stock Down 3.3 %

Shares of Kazia Therapeutics stock traded down $0.12 during trading on Friday, reaching $3.55. 44,207 shares of the company traded hands, compared to its average volume of 404,454. The company has a 50 day moving average price of $5.03 and a 200-day moving average price of $4.11. Kazia Therapeutics has a 1-year low of $1.87 and a 1-year high of $15.80.

Hedge Funds Weigh In On Kazia Therapeutics

A hedge fund recently bought a new stake in Kazia Therapeutics stock. MAI Capital Management purchased a new stake in shares of Kazia Therapeutics Limited (NASDAQ:KZIA) in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 1,363,894 shares of the company’s stock, valued at approximately $586,000. MAI Capital Management owned approximately 51.66% of Kazia Therapeutics at the end of the most recent quarter. Institutional investors and hedge funds own 30.89% of the company’s stock.

Kazia Therapeutics Company Profile

Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company’s lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3.